Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity
1990

Gamma Interferon and Breast Cancer Cell Resistance

publication Evidence: moderate

Author Information

Author(s): N. Jabrane-Ferrat, F. Calvo, A. Faille, J.F. Lagabrielle, N. Boisson, A. Quillet, D. Fradelizi

Primary Institution: Laboratoire de Pharmacologie, Universite Paris 7 et Unite 204 INSERM

Hypothesis

Does gamma interferon treatment increase the resistance of breast cancer cells to immune cell cytotoxicity?

Conclusion

Gamma interferon treatment increases MHC class I expression on breast cancer cells, making them more resistant to destruction by immune cells.

Supporting Evidence

  • Gamma interferon treatment increased MHC class I expression on breast cancer cells.
  • IFN-y treated cells showed resistance to NK and LAK cell lysis.
  • Monoclonal antibodies could restore lysis of IFN-y treated cells.

Takeaway

Gamma interferon helps breast cancer cells hide from the immune system by making them look more normal.

Methodology

The study involved treating breast cancer cell lines with gamma interferon and measuring their susceptibility to immune cell lysis.

Participant Demographics

The study used human breast cancer cell lines T47D and ZR75-1.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication